← All trials
NCT04674189
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2020
- Primary completion
- Jun 30, 2021
- Completion date
- Apr 30, 2022
- First posted
- Dec 19, 2020
- Last posted
- Dec 19, 2020
- Enrollment
- 2520
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CureVac AGLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.